Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Two scientists part of team that discovers the source of the highest energy cosmic rays at the centre of the Milky Way
2016-03-22

Description: Giant molecular clouds  Tags: Giant molecular clouds

Artist's impression of the giant molecular clouds surrounding the Galactic Centre, bombarded by very high energy protons accelerated in the vicinity of the central black hole and subsequently shining in gamma rays.
Artist's impression: © Dr Mark A. Garlick/ H.E.S.S. Collaboration

Spotlight photo:
Dr Brian van Soelen and Prof Pieter Meintjes of the UFS Department of Physics.
Photo: Charl Devenish

H.E.S.S. (High Energy Stereoscopic System) scientists publically revealed their latest galactic discovery in the international science journal, Nature, on 16 March 2016. These scientists were able to pinpoint the most powerful source of cosmic radiation – which, up to now, remained a mystery.

Part of this team of scientists are Prof Pieter Meintjes and Dr Brian van Soelen, both in the University of the Free State (UFS) Department of Physics. Dr Van Soelen explains that they have discovered a proton PeVatron – a source that can accelerate protons up to energies of ~1 PeV (10^15 eV) – at the centre of the Milky Way. The supermassive black hole called Sagittarius A has been identified as the most plausible source of this unprecedented acceleration of protons.

The protons are accelerated to Very High Energy (VHE) gamma rays. The energy of these protons are 100 times larger than those achieved by the Large Hadron Collider at CERN (the European Organization for Nuclear Research).

According to Dr Van Soelen, the fact that this research has been published in Nature demonstrates the importance and pioneering nature of the research conducted by H.E.S.S. The H.E.S.S. observatory – operational in Namibia – is a collaboration between 42 scientific institutions in 12 countries.

In 2006, H.E.S.S. was awarded the Descartes Prize of the European Commission – the highest recognition for collaborative research – and in 2010 the prestigious Rossi Prize of the American Astronomical Society. The extent of the observatory’s significance places it among the ranks of the Hubble Space Telescope and the telescopes of the European Southern Observatory in Chile.

“The next generation VHE gamma-ray telescope,” Dr Van Soelen says, “will be the Cherenkov Telescope Array (CTA), which is currently in the design and development stage.” Both Dr Van Soelen and Prof Meintjes are part of this project as well.

H.E.S.S. has issued a complete statement about the paper published in Nature.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept